Research Analysts Set Fiscal 2026 Earnings Expectations for Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS – Get a rating) – Equity research analysts at Jefferies Financial Group released their fiscal 2026 earnings per share estimates for Ionis Pharmaceuticals in a report released Thursday, February 24. Jefferies Financial Group analyst E. Yang expects the company to post earnings per share of ($2.60) for the year.
Several other research companies have also published reports on IONS. SVB Leerink cut its target price on Ionis Pharmaceuticals from $34.00 to $29.00 and set a “market performance” rating on the stock in a research note on Friday. William Blair upgraded Ionis Pharmaceuticals from a “market performer” rating to an “outperformer” rating in a Tuesday, Dec. 14 research note. BMO Capital Markets took over coverage from Ionis Pharmaceuticals in a Friday, Dec. 10 research note. They issued a “buy” rating and a target price of $65.00 on the stock. Bank of America downgraded Ionis Pharmaceuticals from a “buy” rating to an “underperform” rating and reduced its target price for the company from $40.00 to $30.00 in a Tuesday, Feb. 1 research note . Finally, Needham & Company LLC lowered its price target on Ionis Pharmaceuticals from $84.00 to $60.00 and set a “buy” rating on the stock in a Thursday, November 4 research note. Two equity research analysts gave the stock a sell rating, five issued a hold rating and four gave the company a buy rating. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $45.05.
IONS stock opened at $31.78 on Monday. The company has a debt ratio of 2.34, a current ratio of 7.71 and a quick ratio of 7.62. The company has a 50-day moving average price of $31.72 and a 200-day moving average price of $33.13. The company has a market capitalization of $4.49 billion, a P/E ratio of -83.63 and a beta of 0.88. Ionis Pharmaceuticals has a 1-year low of $25.04 and a 1-year high of $56.01. Ionis Pharmaceuticals (NASDAQ: IONS – Get a rating) last released its quarterly earnings data on Thursday, February 24. The company reported earnings per share of $1.41 for the quarter, beating the consensus estimate of $0.80 by $0.61. The company posted revenue of $440.00 million in the quarter, versus a consensus estimate of $284.08 million. Ionis Pharmaceuticals posted a negative return on equity of 4.68% and a negative net margin of 3.45%. The company’s quarterly revenue increased 51.7% year over year. In the same period a year earlier, the company posted ($2.44) earnings per share.
Major investors have recently changed their positions in the company. Amalgamated Bank increased its stake in Ionis Pharmaceuticals by 37.0% in the second quarter. Amalgamated Bank now owns 26,933 shares of the company valued at $1,074,000 after acquiring an additional 7,267 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Ionis Pharmaceuticals by 2.5% in the second quarter. Charles Schwab Investment Management Inc. now owns 713,960 shares of the company valued at $28,480,000 after acquiring an additional 17,464 shares during the period. Marshall Wace LLP acquired a new position in Ionis Pharmaceuticals in the second quarter valued at approximately $7,054,000. Kennedy Capital Management Inc. increased its stake in the shares of Ionis Pharmaceuticals by 4.0% during the 2nd quarter. Kennedy Capital Management Inc. now owns 8,329 shares of the company worth $332,000 after purchasing 321 additional shares during the period. Finally, Candriam Luxembourg SCA increased its stake in Ionis Pharmaceuticals shares by 31.5% during the 3rd quarter. Candriam Luxembourg SCA now owns 726,359 shares of the company worth $24,361,000 after purchasing an additional 173,793 shares during the period. 83.97% of the shares are held by institutional investors.
About Ionis Pharmaceuticals (Get a rating)
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through Ionis Core and Akcea Therapeutics segments. The Ionis Core segment leverages a novel drug discovery platform to generate a drug pipeline. The Akcea Therapeutics segment develops and markets drugs for cardiometabolic diseases.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Ionis Pharmaceuticals right now?
Before you consider Ionis Pharmaceuticals, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Ionis Pharmaceuticals was not on the list.
While Ionis Pharmaceuticals currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here